Willem Den Otter

Amsterdam UMC Location VUmc

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Hub F. J. Dullens

University Medical Center Utrecht

Jan Willem Koten

University of Graz

Peter A. Steerenberg

National Institute for Public Health and the Environment

John J. L. Jacobs

LifeTec Group (Netherlands)

Roel A. de Weger

University Medical Center Utrecht

E. J. Ruitenberg

Robert Bosch (India)

Linda A. Everse

Utrecht University

Victor P. M. G. Rutten

Utrecht University

K. E. W. P. Tan

University of Amsterdam

R.A. De Weger

Utrecht University

Cooperative Institutions

Utrecht University

186

Heidelberg University

University of Amsterdam

Radboud University Nijmegen

University Medical Center Utrecht

Inserm

Centre National de la Recherche Scientifique

National Institute for Public Health and the Environment

University Hospital Heidelberg

Vrije Universiteit Amsterdam

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Macrophage-Like Cells as Research Tools in Transfer Experiments

Immunobiology (1983)

Henk Van Loveren Willem Den Otter

10.1016/s0171-2985(83)80014-x

Cite

Citations (2)

Immunotherapy of bovine ocular squamous cell carcinoma: isolation, culture and characterization of lymphocytes present in the tumor.

PubMed (1991)

Victor P. M. G. Rutten W. A. C. De Jong W. R. Klein Willem Den Otter P. A. Steerenberg

Bovine ocular squamous cell carcinoma (BOSCC) is sensitive to intralesional immunotherapy with BCG or recombinant human IL-2 (rhIL-2). The mechanism of tumor regression is as yet unclear. Alterations in the concentration of IL-2 (and possibly other factors) in the tumor, due to regional injection or induction by BCG, may induce killer cell activity and thus tumor regression. To investigate this, lymphocytes were isolated by mechanical fractionation of biopsies of BOSCC. Growth, phenotypical, and functional characteristics were studied. TIL could be isolated and grown from all biopsies of BOSCC. An estimated increase in cell number of 50-150 fold was observed during 5-7 weeks of culture. FACS analysis of a limited number of the TIL cultures showed a characteristic shift in phenotypes until day 28 of culture. CD2+ cells (50-70%), and as a consequence of this CD2- cells, remained stable in number. The number of CD8+ cells increased. CD4+ cells were detected in low numbers by day 28. Prolonged culture resulted in an increase of CD2- gamma delta + cells, CD2+4-8- cells, and occasionally of both CD8+ and CD2+ cells. In 51Cr release assays TIL showed cytotoxicity for BOSCC-derived tumor cell lines in general, which increased transiently by cocultivation with tumor cells. Killing of YAC-1, and P815 was far less efficient. Preferential killing of autologous cell lines was not seen. In conclusion, TIL from bovine ocular squamous cell carcinomas can be cultured in the presence of rhIL-2, which induces cytotoxic activity for BOSCC-derived tumor cells. Cells responsible for killing in vitro and potentially for regression of the tumor after immunotherapy with BCG or rhIL2 cannot yet be identified. Depletion and blocking experiments are being conducted in order to identify the cells (CD2+8+, CD2-gamma delta + or other CD2 +/-) responsible for killing.

Source

Cite

Citations (5)

Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas

Veterinary Immunology and Immunopathology (2005)

Rachel Stewart Agnieszka Masztalerz John J. L. Jacobs Willem Den Otter

Combination therapy

10.1016/j.vetimm.2005.03.002

Cite

Citations (11)

High parental age is associated with sporadic hereditary retinoblastoma: the Dutch retinoblastoma register 1862-1994

Human Genetics (1996)

Annette C. Moll Saskia M. Imhof D. Joop Kuik L.M. Bouter Willem Den Otter

Retinoblastoma

Paternal age

10.1007/s004390050168

Cite

Citations (52)

Differences in the Induction of Macrophage Cytotoxicity by the Specific T Lymphocyte Factor, Specific Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Arming Factor (SMAF), and the Lymphokine, Macrophage Activating Factor (MAF)

Immunobiology (1989)

Jan Willem de Groot R.A. De Weger Rob J. Vandebriel Willem Den Otter

Macrophage-activating factor

10.1016/s0171-2985(89)80012-9

Cite

Citations (8)

Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains

Glycobiology (1993)

Hans Voshol Hub F. J. Dullens Willem Den Otter Johannes F.G. Vliegenthart

Journal Article Cell surface glycoconjugates as possible target structures for human natural killer cells: evidence against the involvement of glycolipids and N-linked carbohydrate chains Get access Hans Voshol, Hans Voshol 1Utrecht University, Bijvoet Center, Department of Bio-Organic ChemistryPO Box 80075, 3508 TB Utrecht Search for other works by this author on: Oxford Academic PubMed Google Scholar Hub F.J. Dullens, Hub F.J. Dullens 2Utrecht University, Department of PathologyPO Box 85500, 3508 GA Utrecht, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Willem Den Otter, Willem Den Otter 2Utrecht University, Department of PathologyPO Box 85500, 3508 GA Utrecht, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Johannes F.G. Vliegenthart Johannes F.G. Vliegenthart 3 1Utrecht University, Bijvoet Center, Department of Bio-Organic ChemistryPO Box 80075, 3508 TB Utrecht 3To whom correspondence should be addressed Search for other works by this author on: Oxford Academic PubMed Google Scholar Glycobiology, Volume 3, Issue 1, February 1993, Pages 69–76, https://doi.org/10.1093/glycob/3.1.69 Published: 01 February 1993 Article history Received: 28 September 1992 Accepted: 17 November 1992 Published: 01 February 1993

Glycoconjugate

10.1093/glycob/3.1.69

Cite

Citations (9)

Ocular squamous cell carcinoma in Simmental cattle in Zimbabwe.

PubMed (1995)

Willem Den Otter F.W. Hill W. R. Klein Linda A. Everse E. J. Ruitenberg

In Zimbabwe, ocular squamous cell carcinoma (OSCC) was frequently observed in 5 breeding herds of Simmental cattle, a Bos taurus breed originating from Switzerland. In these herds, initial signs of OSCC were already noticeable in cattle about 3 years old. Gradually, OSCC prevalence increased, and 36 to 53% of cattle over 7 years old had 1 or more tumors. More tumors developed in Simmental cattle with periorbital white skin than in cattle with periorbital pigmented skin. Other breeds of cattle (eg, Friesian) also are partly white-faced and live in Zimbabwe in a comparable environment; yet, OSCC prevalence was lower in those breeds.

Cattle Diseases

White (mutation)

Source

Cite

Citations (9)

Vesicles for tumour-associated antigen presentation to induce protective immunity: preparation, characterization and enhancement of the immune response by immunomodulators

Journal of Controlled Release (1994)

Joep J. Bergers Willem Den Otter Daan J.A. Crommelin

Phosphatidylethanolamine

10.1016/0168-3659(94)90077-9

Cite

Citations (5)

Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Pharmaceutical Research (1993)

Joep J. Bergers Willem Den Otter Hub F. J. Dullens Catherina T. M. Kerkvliet Daan J.A. Crommelin

Phosphatidylglycerol

Phosphatidylethanolamine

10.1023/a:1018913912580

Cite

Citations (32)

Therapeutic efficacy of IL‐2‐loaded hydrogels in a mouse tumor model

International Journal of Cancer (2001)

Cornelis J. De Groot J.A. Cadée Jan‐Willem Koten Wim E. Hennink Willem Den Otter

Abstract Interleukin‐2 (IL‐2) is a highly effective anticancer drug if it is applied locally for 5 consecutive days. In most cases this requires 5 invasive treatments, which is not usually acceptable for either the patient or the clinician. For this reason we have developed dextran‐based hydrogels from which the required amount of encapsulated IL‐2 (1–4 × 10 6 IU of IL‐2) is gradually released during 5–10 days. Initially IL‐2‐containing macroscopic cylinder‐shaped gels (implants), and later IL‐2‐containing injectable microspheres, were developed. These preparations were characterized in vitro , and the therapeutic activity was tested in DBA/2 mice with SL2 lymphosarcoma. The therapy was given to mice with a large and extensively metastasized tumor load (at least 5% of the body weight). If 1–4 × 10 6 IU of IL‐2 was slowly released from the hydrogels over a period of 5–10 days, the therapeutic effects were very good and comparable to the effects of free IL‐2 injections for 5 consecutive days. In conclusion, dextran‐based hydrogels are promising systems for the controlled release of IL‐2. © 2001 Wiley‐Liss, Inc.

Therapeutic effect

Therapeutic index

10.1002/ijc.10167

Cite

Citations (35)